Clinical trial NCT00363259: Pegintron Induction Therapy in HCV Non-Responders
Official title: Pegintron Induction Therapy in Previous Non-Responders With Chronic HCV: A Dutch Multicenter Randomized Controlled Trial. (PIT-Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hepatitis C
Lead sponsor: Foundation for Liver Research
Sponsor class: OTHER
First posted: 2006-08-15
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the sustained virological response rate at 24 weeks after the end of experimental treatment (induction and 72 weeks) to that of standard 48 weeks treatment with PEG-inteferon alfa-2b and ribavirin in patients with chronic hepatitis C previous unresponsive to interferon alfa monotherapy or interferon alfa/ribavirin combination therapy.


Eligibility criteria: Inclusion Criteria:

* chronic hepatitis C
* non-response or relapse to previous interferon therapy with or without ribavirin for at least 3 months at any previous time
* detectable serum HCV-RNA
* elevated serum ALT activity documented on at least two occasions within the past 12 months, with at least one during the 90 day screening period preceding the initiation of test drug dosing
* liver biopsy findings (during screening or within previous 12 months) consistent with active fibrosis (haemophiliacs are excluded from biopsies)
* compensated liver disease (Child-Pugh Grade A clinical classification)
* negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
* all fertile males and females receiving ribavirin and their fertile or potentially fertile partners must be advised to use two forms of effective contraception (combined) during treatment and during the 6 months after end of treatment

Exclusion Criteria:

* history or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigator, unsuitable for the study
* women with ongoing pregnancy or breast feeding
* therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) \<3 months prior to the first dose of study drug
* any investigational drug \<6 weeks prior to the first dose of study drug
* positive test at screening for HBsAg, anti-HIV Ab
* history or other evidence of bleeding from esophageal varices, ascites, or other conditions consistent with decompensated liver disease (Child-Pugh Grade B or C clinical classification)
* Signs or symptoms of hepatocellular carcinoma
* history or other strong evidence of a medical condition associated with chronic liver disease other than HCV (e.g., primary hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures
* Hb \<7.5 mmol/l in women or \<8.6 mmol/l in men at screening
* any patient with an increased baseline risk for anaemia (e.g. thalassemia, spherocytosis, etc) or for whom anaemia would be medically problematic
* neutrophil count \<1500 cells/mm3 or platelet count \<80,000 cells/mm3 at screening
* serum creatinine level \>1.5 times the upper limit of normal at screening
* history of severe psychiatric disease, especially depression
* history of a severe seizure disorder or current anticonvulsant use
* history of immunologically mediated disease
* history or other evidence of chronic pulmonary disease associated with functional limitation
* history of severe allergies
* history of symptomatic and/or significant cardiovascular disease
* poorly controlled diabetes mellitus
* history of major organ transplantation with an existing functional graft
* hyper- or hypothyroidism
* evidence of severe retinopathy
* evidence of drug abuse (including excessive alcohol consumption within one year before study entry

Primary outcomes:
measure: sustained virological response (HCV-RNA negative 24 weeks after end of treatment)
Secondary outcomes:
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: OLVG
city: Arnhem
country: Netherlands
facility: Rijnstate Ziekenhuis
city: Heerlen
country: Netherlands
facility: Atrium Medisch Centrum
city: Leiden
country: Netherlands
facility: LUMC
city: Rotterdam
country: Netherlands
facility: Erasmus MC
city: Terneuzen
country: Netherlands
facility: Ziekenhuis Zeeuws Vlaanderen
city: Utrecht
country: Netherlands
facility: UMC
Study officials:
affiliation: Erasmus Medical Center
name: Rob J de Knegt, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: